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Doxorubicin (DOX) is a member of the anthracycline class of 
chemotherapeutic agents used for the treatment of many common 
human cancers including aggressive non-Hodgkin’s lymphoma [1, 2].  
However, DOX is highly toxic in humans resulting in severe 
suppression of hematopoiesis, gastrointestinal toxicity [3], and 
cardiac toxicity [4].  To date, several approaches including its 
delivery using liposomes (DOXIL) [5] have been developed to 
reduce the toxicity and enhance the clinical utility of this highly 
active antineoplastic agent. 
Carbon nanotubes have unique mechanical, optical and 
chemical properties with broad potential biomedical applications 
including imaging and cancer therapeutics [6-13]. Carbon nanotubes 
have been used as novel delivery vehicles in vitro to effectively 
shuttle various bio-molecules including drugs [13, 14], plasmid DNA 
[15] and small interfering RNA (siRNA) [16, 17] into cells via 
endocytosis [18]. On the other hand, the unique optical properties of 
single walled carbon nanotubes (SWNTs) have been utilized for 
biological imaging [7-11] as well as cancer cell destruction [19]. 
Various groups have studied the behaviors of this material in animal 
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models [20-23]. Well functionalized SWNTs have been found to be 
non-toxic in mice over several months and can be gradually excreted 
by the biliary pathway from reticuloendothelial systems (RES) into 
feces, with the majority of SWNTs cleared within two months [20, 21]. 
Here, we explored the possibility of using supramolecular π-π 
stacking to load a cancer chemotherapy agent, doxorubicin (DOX), 
onto branched polyethylene glycol (PEG) functionalized SWNTs for 
in vivo drug delivery applications. We found that our new drug 
formulation, SWNT-DOX, afforded significantly enhanced 
therapeutic efficacy and a marked reduction in toxicity compared to 
free DOX and DOXIL.  
It has been found that the surface of PEGylated SWNTs could 
be efficiently loaded with DOX via supramolecular π-π stacking 
(Fig. 1a) [13]. For Hipco SWNTs used in this work, the binding 
energy of DOX on nanotubes is estimated to be ~48 kJ/mol in water 
[13]. Branched PEG was used here to achieve prolonged blood 
circulation time [21]. The SWNT-DOX complex had an average 
length of 100 nm and diameter of 2~3 nm as determined using an 
atomic force microscope (AFM) (Fig. 1b). The loading ratio of 
DOX was determined by UV-VIS-NIR absorption spectra (Fig. 1c). 
Depending on solution pH and DOX concentration, DOX loading on 
nanotubes ranged from 1 to 4 grams DOX per gram of SWNTs [13]. 
We chose a loading of ~2.5 gram DOX per gram of SWNTs for the 
experiments in this work. We found that SWNT-DOX remained 
cytotoxic to cancer cells in vitro (Supplementary Fig. S1), likely due 
to the release of DOX from nanotubes inside cell endosomes and 
lysosomes with acidic pH [13]. 
In order to investigate the in vivo pharmacokinetics and 
biodistribution, SWNT-DOX was injected via tail vein into SCID 
mice bearing Raji lymphoma xenografts. Blood was drawn at 
different time points post injection with DOX concentrations 
measured by fluorescence spectra following published protocols [24]. 
After being loaded onto nanotubes, the DOX circulation half-life 
increased from 0.21 hours for free DOX to 2.22 hours for the 
SWNT-DOX formulation while the total area under curve (AUC0-∞) 
also increased from 5.3 mg·h/L to 78.8 mg·h/L (Fig. 2a). Mice were 
sacrificed at 6 hours post injection with major organs harvested and 
homogenized for DOX extraction [24]. The concentration of DOX in 
each organ was measured by fluorescence intensity. Free DOX 
tumor uptake was 0.68 percent of injected dose per gram tissue 
(%ID/g).  Tumor uptake of DOX doubled to 1.51 %ID/g for SWNT-
DOX, which was likely due to the prolonged circulation of SWNT-
DOX that facilitated the enhanced permeability and retention (EPR) 
effect observed with various nanomaterials (Fig. 2b) [25]. As 
expected, in the SWNT-DOX formulation, DOX accumulated in the 
RES including liver and spleen. Despite the high RES uptake, 
SWNT-DOX did not show obvious hepatic toxicity from histology 
studies (Supplementary Fig. S4). The combined biodistribution 
information of SWNTs determined by Raman scattering and DOX 
detected by fluorescence (Supplementary Fig. S2) indicates that 
although most SWNT-DOX is still in the associated form in the first 
few hours after administration, the loaded DOX slowly dissociates 
from nanotubes and is excreted via kidneys. Most nanotubes are too 
large to be excreted by the kidneys and instead are slowly excreted 
via the biliary system into the feces [21]. 
The in vivo therapeutic efficacy of the SWNT-DOX complex 
was also investigated. SCID mice bearing Raji lymphoma xenograft 
tumors were treated weekly with SWNT-DOX, free DOX, or 
DOXIL.   Sizes of subcutaneous tumors were measured over two 
weeks.  Tumors in untreated controls rapidly increased by 7.53 ± 
0.99 fold.  The SWNT-DOX (5 mg/kg) treated group showed a 
greater inhibition of tumor growth than free DOX at the equivalent 
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dose (2.15 ± 0.16 fold tumor growth versus 2.90 ± 0.19, respectively, 
p = 0.016) (Fig. 4a, 5a).  Tumors in mice treated with plain SWNT 
increased by 6.44 ± 0.42 fold, (versus untreated, p = 0.34), 
indicating that SWNTs alone do not have therapeutic efficacy 
(Supplementary Fig. S3).  Mice treated with DOXIL (5 mg/kg) 
developed severe treatment toxicity and mortality, as discussed 
below, but the DOXIL-treated mice that did remain alive at 14 days 
exhibited partial tumor regression to 0.88 ± 0.19 of original size.  
Thus, loading of DOX onto SWNT increased the therapeutic 
efficacy over free DOX, but not DOXIL.  
To evaluate toxicity of SWNT-DOX formulation, we 
measured body weight of mice in each cohort.  Mice treated with 
free DOX (5 mg/kg) and DOXIL (5 mg/kg) each exhibited a 19% 
and 17% decrease in weight within 2 weeks, respectively (Fig. 3b), 
and appeared to be both thinner and weaker after treatment (Fig. 4a, 
Supplementary Fig. S5).  Treatment with DOX and DOXIL resulted 
in 20% and 40% mortality, respectively.  In marked contrast, mice 
treated with SWNT-DOX had stable weight and no mortalities. In 
another control experiment, sequential administration of SWNT 
followed by DOX showed similar efficacy and toxicity as free DOX 
(Supplementary Fig. S3), suggesting that loading of DOX onto 
SWNT is essential for the treatment outcomes. We note that SCID 
mice used in our study appeared to exhibit more DOX toxicity than 
as described in literature for several other mouse strains including 
nude mice [5, 26].  Thus in our xenograft model of aggressive B cell 
lymphoma, loading of DOX onto SWNT significantly attenuated 
toxicity associated with free DOX and DOXIL. 
We considered that the reduced toxicity of SWNT-DOX might 
allow us to administer higher doses of DOX.  Indeed, SWNT-DOX 
administered at a 10 mg/kg dose improved treatment efficacy even 
further, with tumor size at 2 weeks only 1.64 ± 0.11 fold increased 
(p = 0.018 versus 5 mg/kg SWNT-DOX, p < 0.001 versus 5 mg/kg 
free DOX) (Fig. 3a). Furthermore, SWNT-DOX (10 mg/kg) 
treatment resulted in neither a significant decrease in body weight 
nor an increase in mortality. In marked contrast, 10 mg/kg free DOX 
was a uniformly lethal dose within 2 weeks of treatment. Mouse 
tissues from SWNT-DOX (10 mg/kg) did not exhibit gross 
microscopic gastrointestinal, cardiac, hepatic or renal toxicity (Fig. 
4b, S4).  In marked contrast, mice treated with DOX alone (5 
mg/kg) demonstrated disruption of the intestinal lining consistent 
with gastrointestinal mucositis, exhibiting complete loss of 
columnar epithelial cells at the tips of villi, thus exposing the 
underlying connective tissue core of lymphatic capillaries, blood 
capillaries and smooth muscle (Fig. 4b).  Therefore, by decreasing 
gastrointestinal toxicity, SWNT-DOX also improved the dose 
intensity that could be achieved in mice, further enhancing the 
treatment efficacy. 
Finally, to compare overall clinical efficacy as defined by 
morbidity-free survival, Kaplan-Maier analysis was performed.  In 
this analysis, mice in each cohort were scored either when tumor 
volume increased by 2-fold, when body weight decreased by 10%, 
or when they died during treatment.  In this model, we found that 
SWNT-DOX formulation was superior to DOX alone or DOXIL 
(DOX versus SWNT-DOX 5mg/kg or 10mg/kg, p< 0.001; DOXIL 
versus SWNT-DOX 5mg/kg, p=0.013; DOXIL versus SWNT-DOX 
10mg/kg, p< 0.001) (Fig. 4c).  We conclude that supramolecular π-π 
stacking of a therapeutic agent onto SWNTs provides a novel 
method to efficiently deliver high dose chemotherapy with an 
increase in clinical efficacy. 
Our strategy has critical advantages over a recently described 
approach in paclitaxel (PTX) delivery with SWNTs[12]. First, DOX 
is directly loaded on SWNT surface by simple non-covalent π-π 
stacking, achieving much higher drug loading capacity on nanotubes 
(up to 4g DOX / 1g SWNT), due to the ultra-high surface area of 
SWNTs and the nature of non-covalent loading that is not limited by 
the number of available functional groups. It has been previously 
estimated that ~70-80% of nanotube surface can be occupied by 
stacked DOX [13]. Our strategy can be easily extended to a wide 
range of lipophilic aromatic drugs including daunarubicin,gefitinib 
and camptothecin analogs [27]. Second, unlike SWNT-PTX 
conjugate, in which the hydrophobic PTX is exposed to outside 
environment and reduces the circulation half-life of the conjugate, 
DOX in the SWNT-DOX complex is stacked on nanotube sidewall 
and thus protected by long branched PEG coating, allowing more 
stable drug loading and significantly prolonged blood circulation.   
There are several possible reasons why SWNT-DOX exhibits 
greater therapeutic efficacy and less toxicity than equimolar 
amounts of free DOX to treated mice.  SWNT-DOX has a larger 
size that hampers its filtration through glomerulus, unlike free DOX, 
which is rapidly cleared out from blood circulation by renal 
excretion. The branched PEG coating attenuates the clearance of 
SWNT-DOX by macrophages in RES, causing SWNT-DOX to have 
a prolonged blood circulation half life [21], which allows repeated 
passing of drug conjugates through tumor vessels and increased 
tumor uptake by the EPR effect.  
Our previous studies suggest that DOX loaded on SWNTs is 
stable at neutral pH but released in acidic environments [13]. The 
tumor microenvironment is slightly acidic [28], facilitating the 
dissociation of DOX from its SWNT carrier [13].  Normal organs and 
tissues, however, have a neutral pH, at which SWNT-DOX remains 
stable without releasing free DOX.  SWNT-DOX that was detected 
in the intestinal tissues likely remained conjugated without releasing 
free DOX because epithelial cells that line the gastrointestinal tract  
maintain a neutral to alkaline environment [29]. Unlike DOX 
molecules which can freely diffuse out from blood vessels and reach 
intestinal tissues including epithelial intestinal lining, SWNT-DOX 
has reduced ability to undergo such diffusion due to its larger size 
that may limit access to intestinal tissues that are far from blood 
vessels in the intestine. This decrease in gastrointestinal epithelial 
toxicity is likely to contribute to the reduced toxicity of SWNT-
DOX (Fig. 4b).  However, the mechanism of our observed toxicity 
difference between SWNT-DOX and DOXIL remains to be 
explored (Fig. S5). Further studies are required to compare the 
clinical efficacy and toxic effects of SWNT-DOX and DOXIL at 
various doses. 
In contrast to many other inorganic nanoparticles such as 
quantum dots that contain toxic heavy metals, carbon nanotubes are  
composed purely of carbon atoms that are relatively non-toxic. 
Compared with other traditional drug carriers such as polymers and 
liposomes, SWNTs have valuable features that allow both the ability 
to image cancer as well as to deliver a therapy. Near-infrared (NIR) 
fluorescence, Raman scattering or photo-acoustic contrast properties 
of SWNTs can be utilized for both in vitro and in vivo imaging [7-11]. 
The strong NIR optical absorption ability of SWNTs can be used for 
photothermal therapy [19], that could be combined with 
chemotherapy delivered by nanotubes for enhanced treatment 
efficacy.  In addition to passive tumor targeting relying on the EPR 
effect, active in vivo tumor targeting of SWNTs has been achieved 
by conjugation of targeting peptides [23] or antibodies [22] to 
nanotubes. Thus carbon nanotubes have the potential to be a 
effective mechanism of drug delivery that could improve therapeutic 
efficacy and reduce drug related toxicities while simultaneously 
serving as an imaging modality for cancer.  
 3
Experimental Section 
DOX loading on functionalized SWNTs.. Phospholipid-
branched PEG (7 kDa) was synthesized as described earlier [21]. Raw 
Hipco SWNTs (0.2 mg/mL) were sonicated in a 0.2 mM solution 
phospholipid–branched PEG for 30 min with a cup-horn sonicator 
followed by centrifugation at 24,000 g for 6 h, yielding a suspension of 
SWNTs with non-covalent phospholipid–branched PEG coating in the 
supernatant [13, 16, 21]. Excess surfactant was removed by repeated 
filtration through a 100 kDa MWCO filter (Millipore) and extensive 
washing with water. 
DOX loading onto PEGylated SWNTs was done by mixing 0.5 
mM of DOX with the PEGylated SWNTs at a nanotube concentration 
of ~0.05 mg/ml (~300 nM) at pH 8 for overnight. Unbound excess 
DOX was removed by filtration through a 100 kDa filter and washed 
thoroughly with water until the filtrate became free of reddish color 
(corresponding to free DOX). The formed SWNT-DOX complex was 
characterized by UV-Vis-NIR absorbance spectra with a Cary-6000i 
spectrophotometer as described previously and stored at 4°C. 
 
In vivo circulation and biodistribution studies. Blood circulation 
was measured by drawing ~15 µl blood from the tail vein of Raji tumor 
bearing SCID mice post injection of free DOX or SWNT-DOX. The 
blood samples were dissolved in a lysis buffer 1 (1% SDS, 1% Triton 
X-100, 40 mM Tris Acetate, 10 mM EDTA, 10 mM DTT) with brief 
sonication. The concentration of SWNTs in the blood was measured 
by a Raman method [21]. DOX measurement was carried out following 
the protocol previously reported with minor modification [24]. Briefly, 
DOX was extracted by incubating blood samples in 1 ml of 0.75 M 
HCl in isopropanol (IPA) at -20°C overnight. After centrifugation at 
24,000 g for 15 minutes, fluorescence of the supernatant was 
measured using a fluorolog-3 fluorometer. Note that DOX loaded on 
SWNTs can be completely pulled off from nanotubes by the extraction 
solution with ~100% recovery of fluorescence (DOX fluorescence is 
quenched once loaded on nanotubes). 
To study biodistribution, mice were sacrificed at 6 h post 
injection of free DOX or SWNT-DOX. The organs/tissues (0.1 – 0.2 g 
of each) were wet-weighed and homogenized in 0.5 ml of lysis buffer 
2 (0.25M sucrose, 40 mM Tris Acetate, 10 mM EDTA) with a 
PowerGen homogenizer (Fisher Scientific). For DOX measurement, 
200 µl of tissue lysate was mixed with 100 µl of 10% Titron X-100. 
After strong vortex, 1 ml of extraction solution (0.75 M HCl in IPA) 
was added and the samples were incubated at -20°C overnight. After 
centrifugation at 24,000 g for 15 min, fluorescence of the supernatant 
was measured.  
 
Treatment of in vivo lymphoma xenograft model. SCID mice were 
subcutaneously injected with 10 million Raji cells.  Treatment was 
initiated when the tumors reached a size of ~400 mm3 (2-3 weeks 
after tumor inoculation). Tumor bearing mice were intravenously 
injected with different formulations of DOX including free DOX, SWNT, 
SWNT-DOX and DOXIL at 5 mg/kg of normalized DOX dose (or 10 
mg/kg for SWNT-DOX) as well as related controls weekly. The tumor 
sizes were measured by calipers three times a week and volume was 
calculated according to the formula (tumor length) X (tumor width)2/2. 
Relative tumor volumes were calculated as V/V0 (V0 was the tumor 
volume when the treatment was initiated).  Mice were weighed with 
the relative body weights normalized to their initial weights. Tumors 
and organs were collected at the end of treatment, fixed in formalin, 
embedded in paraffin and sectioned using a microtome. Standard 
hematoxylin and eosin  (H&E) staining was carried for histological 
examinations. 
 
Statistical analysis. Quantitative data were expressed as mean ± 
standard errors of the mean (SEM). Means were compared using 
student’s t-test. P values < 0.05 were considered statistically 
significant. 
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Figure 1. Doxorubicin was efficiently loaded on PEGylated SWNTs by π-π stacking. (a) A schematic drawing of SWNT-
DOX complex. SWNTs were coated with biocompatible branched PEG with hydrophobic phospholipid anchored on the 
nanotube surface. DOX was densely packed on the aromatic nanotube surface via supramolecular π-π stacking. (b) An atomic 
force microscope (AFM) image of SWNT-DOX complexes. SWNT-DOX have average length of ~100 nm and diameter of 
2~3 nm. Scale bar: 250 nm. (c) UV-VIS-NIR spectra of plain SWNT, SWNT-DOX and free DOX. The DOX loading was 
determined by the absorption peak at 490 nm. 
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Figure 2. The pharmacokinetics and biodistribution of two DOX formulations were studied by fluorescence spectroscopy. (a) 
SWNT-DOX showed prolonged blood circulation compared with free DOX. DOX concentrations in blood from mice treated 
with free DOX and SWNT-DOX were measured by fluorescence spectroscopy at different time points post injection. (b) 
SWNT-DOX had higher tumor specific uptake and RES uptake than free DOX. Biodistribution of DOX in major organs of 
mice was measured 6 h after injection of free DOX and SWNT-DOX. Error bars were based on SEM of triplicate samples. 
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Figure 3. Supramolecular packing of DOX to SWNTs increased clinical efficacy in vivo. Raji tumor bearing SCID mice were 
treated with different DOX formulations once a week at day 0 and day 7.  Tumor sizes and body weights were recorded three 
times a week. (a) SWNT-DOX formulation slowed tumor growth in a dose-dependent manner, showing better efficacy than 
free DOX but not DOXIL. Tumor sizes of untreated (n = 7), 5 mg/kg free DOX treated (n = 10, 2 mice died in the second 
week), 5 mg/kg Doxil treated (n = 5), 5 mg/kg SWNT-DOX treated (n = 10) and 10 mg/kg SWNT-DOX treated (n = 10) mice 
were measured during treatment. p values at 2 weeks: untreated versus DOX 5 mg/kg, p = 0.001; DOX 5 mg/kg versus SWNT-
DOX 5 mg/kg, p = 0.016; DOX 5 mg/kg versus SWNT-DOX 10 mg/kg, p <0.001; SWNT-DOX 5 mg/kg versus SWNT-DOX 
10 mg/kg, p = 0.018. Mean tumor volume normalized to Day 0 +/- SEM is graphed. (b) SWNT-DOX resulted in far less 
weight loss than DOX and DOXIL. Mean body weight normalized to Day 0 +/- SEM is graphed. (c) SWNT-DOX formulation 
resulted in increased morbidity free survival. In the Kaplan-Maier analysis, we scored mice for morbidity when tumor volume 
increased by 2-fold, when body weight decreased by 10%, or when they died during treatment. p values: DOX 5 mg/kg versus 
SWNT-DOX 5mg/kg or 10mg/kg, p < 0.001; DOXIL 5mg/kg versus SWNT-DOX 5mg/kg, p = 0.013; DOXIL 5mg/kg versus 
SWNT-DOX 10mg/kg, p < 0.001) 
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Figure 4. SWNT-DOX showed less in vivo toxicity. (a) Representative photos of mice from different groups were taken at the 
end of treatment.  Mice became visibly thinner after treatment by free DOX. (b) Gastrointestinal toxicity was observed in free 
DOX treated mice but not in SWNT-DOX treated mice. Histological sections of intestinal epithelium showed damage of 
intestinal epithelium in the free DOX treated group. Arrows: area of loss of columnar epithelial cells in tips of villi. Scale bar: 
100 microns.  
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Supplementary Figure S1. SWNT-DOX was tumoricidal against lymphoma cells in vitro. (a) SWNT-DOX 
maintained cytotoxicity on human B-cell lymphoma Raji cells. Raji cells were incubated with free DOX, DOXIL 
and SWNT-DOX at series of concentrations for 3 days. Relative cell viabilities determined by MTS assay (versus 
untreated control) were plotted against DOX concentrations during cell incubation. IC50 values were measured to 
be 76 ± 8.6 nM, 519 ± 11 nM and 218 ± 7.2 nM for free DOX, DOXIL and SWNT-DOX, respectively. (b) Plain 
SWNTs were non-toxic to Raji cells. Relative cell viabilities were plotted against SWNT concentrations (1 nM of 
SWNT corresponded to a weight concentration of 0.17 mg/L). While SWNT-DOX is highly toxic, plain SWNT 
exhibited no noticeable toxicity even at high concentrations after 3 days incubation with Raji cells. Error bars were 
based on standard deviations of triplicate samples.  
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Supplementary Figure S2. In vivo behaviors of the SWNT-DOX complex. (a) Blood circulation of SWNT drug 
carrier and DOX was measured by Raman and fluorescence, respectively, in mice injected with SWNT-DOX.  (b) 
Biodistribution of SWNT and DOX in mice injected with SWNT-DOX showed high RES uptake of both drug and 
drug carrier, indicating that DOX was carried into RES organs by SWNTs. (c) Free DOX was cleared from urine. 
The strong DOX fluorescence in the early urine sample (0.5 h) and low fluorescence at the later time point (4 h) 
indicated rapid renal clearance of free DOX. (d) SWNT-DOX had delayed urinary clearance of dissociated DOX. 
Increased DOX fluorescence was observed in the 4 h urine sample. Probing SWNTs ex vivo by Raman 
spectroscopy was based on our well established protocols published earlier.[1, 2] Error bars were based on SEM of 
triplicate samples.
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Supplementary Figure S3. Plain SWNTs exhibited no obvious effect on either tumor growth or mouse body 
weight change. Raji tumor bearing SCID mice were treated with plain SWNT, free DOX and free DOX plus plain 
SWNT once a week with tumor sizes and body weights recorded. The dose of plain SWNT was equal to that used 
in 5 mg/kg SWNT-DOX. (a) Plain SWNT had no in vivo tumoricidal effect. p values at 2 weeks: untreated versus 
plain SWNT, p = 0.34; DOX 5mg/kg versus DOX 5mg/kg + plain SWNT, p = 0.56. (b) Plain SWNT showed no 
noticeable effect on the mouse body weight change. p values at 2 weeks: untreated versus plain SWNT, p = 0.41; 
DOX 5mg/kg versus DOX 5mg/kg + plain SWNT, p = 0.32. 
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Supplementary Figure S4. Histological sections of liver and kidney from untreated, free DOX 5mg/kg, SWNT-
DOX 5mg/kg and SWNT-DOX 10 mg/kg treated mice showed no obvious abnormality in those organs of various 
groups. Scale bar = 100 μm. 
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Supplementary Figure S5. Representative photos of the DOXIL treated group. (a) Representative photos of 
mice treated with DOXIL (5mg/kg) were taken at the end of treatment. (b) Histological sections of tumor, heart, 
liver and kidney from DOXIL (5mg/kg) treated mice. Toxicity caused by DOXIL treatment does not appear to 
affect these organs. Scale bar = 100 μm 
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